| Name | Title | Contact Details |
|---|---|---|
John Lombardo |
Senior Director, Logistics and Supply Chain | Profile |
Anne Erickson |
Senior Vice President, Chief of Staff | Profile |
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.
National Diabetic Pharmacies is a Salem, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.
Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.
The Supreme Cannabis Company (TSXV: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is a Canadian publicly traded company committed to providing premium brands and products that proudly reflect its consumers, people and uniquely innovative culture. The Company`s portfolio includes its wholly-owned subsidiary and award-winning brand, 7ACRES. 7ACRES is a federally licensed producer of cannabis operating inside a 342,000-square-foot facility in Kincardine, Ontario. 7ACRES is dedicated to providing consumers with a premium-quality product that recognizes its customers are informed, discerning and value a brand and culture that aligns with their principles. 7ACRES brand success has been reflected in its "Brand of the Year" award win at the 2018 Canadian Cannabis Awards, and in provincial supply agreements where 7ACRES` product is consistently listed in the highest brand category available to recreational consumers. The Company`s growing portfolio also includes an equity investment and long-term global distribution partnership with Lesotho-based Medigrow for the exporting of medical-grade cannabis oil. The Supreme Cannabis Company has been a leading innovator in the sector including the design of growing facilities and development of operational excellence metrics. We are confident that together with our flagship brand, proprietary technology and products, truly unique culture, and industry-leading team, we will deliver our shareholders consistent long-term value creation.